Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma.
Jiao XD, Ding LR, Zhang CT, Qin BD, Liu K, Jiang LP, Wang X, Lv LT, Ding H, Li DM, Yang H, Chen XQ, Zhu WY, Wu Y, Ling Y, He X, Liu J, Shao L, Wang HZ, Chen Y, Zheng JJ, Inui N, Zang YS. Jiao XD, et al. Among authors: chen xq, chen y. Transl Lung Cancer Res. 2021 Jul;10(7):3236-3250. doi: 10.21037/tlcr-21-543. Transl Lung Cancer Res. 2021. PMID: 34430361 Free PMC article.
Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types.
Jiao XD, Zhang XC, Qin BD, Liu D, Liu L, Ni JJ, Ning ZY, Chen LX, Zhu LJ, Qin SB, Ying SP, Chen XQ, Li AJ, Hou T, Han-Zhang H, Ye J, Zheng J, Chuai S, Zang YS. Jiao XD, et al. Among authors: chen xq, chen lx. Ann Transl Med. 2020 Jul;8(14):860. doi: 10.21037/atm-20-3807. Ann Transl Med. 2020. PMID: 32793704 Free PMC article.
HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma.
Jia Z, Xing J, Li J, Wang W, Wang Y, Song Y, Yang X, Xue J, Ye J, Li B, Han-Zhang H, Zhao J, Zhang X, Peng F, Chen F, Chen X, Lu Y, Ying S, Wu D, Zhang X, Ma C, Lai L, Ma S, Liang D, Liu P, Li X, Liang N, Li S. Jia Z, et al. Transl Lung Cancer Res. 2021 Mar;10(3):1383-1396. doi: 10.21037/tlcr-21-107. Transl Lung Cancer Res. 2021. PMID: 33889517 Free PMC article.
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
Jiao XD, Qin BD, Wang Z, Liu K, Wu Y, Ling Y, Qin WX, Wang MM, Yuan LY, Barreto SG, Kim AW, Mak K, Li H, Xu YY, Qiu XM, Wu M, Jin M, Xu LC, Zhong Y, Yang H, Chen XQ, Zeng Y, Shi J, Zhu WY, Ding QQ, Jia W, Liu SF, Zhou JJ, Shen H, Yao SH, Guo ZJ, Li T, Zhou PJ, Dong XW, Lu WF, Coleman RL, Akce M, Akladios C, Puccetti F, Zang YS. Jiao XD, et al. Among authors: chen xq. Front Oncol. 2023 Feb 23;13:860711. doi: 10.3389/fonc.2023.860711. eCollection 2023. Front Oncol. 2023. PMID: 36910668 Free PMC article.
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.
Zhang D, Liu X, Shen F, Zhao D, Shi Y, Zhang H, Liu J, Gao X, Chen M, Zhao J, Zhong W, Gao J, He M, Liu Y, Yang X, Qin J, Tang Y, Mu X, Gu Y, Zhang S, Chen X, Pang L, Meng Q, Guo Y, Zhang Y, Li W, Xing P, Cheng Y, Xin T, Li Q, Li Y, Chen J, Gao F, Jin B, Rossi A, Adachi H, Guerrera F, Husain H, Xu Y, Wang M. Zhang D, et al. Transl Lung Cancer Res. 2023 Nov 30;12(11):2229-2244. doi: 10.21037/tlcr-23-577. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38090527 Free PMC article.
1,169 results